Paradigm Biocapital Advisors L.P. is an investment fund managing more than $2.61 trillion ran by David Kim. There are currently 35 companies in Mr. Kim’s portfolio. The largest investments include Nuvalent Inc and Argenx Se, together worth $578 billion.
As of 7th August 2024, Paradigm Biocapital Advisors L.P.’s top holding is 4,571,678 shares of Nuvalent Inc currently worth over $347 billion and making up 13.3% of the portfolio value.
In addition, the fund holds 538,139 shares of Argenx Se worth $231 billion.
The third-largest holding is Arcellx Inc worth $212 billion and the next is Revolution Medicines Inc worth $204 billion, with 5,259,089 shares owned.
Currently, Paradigm Biocapital Advisors L.P.'s portfolio is worth at least $2.61 trillion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Paradigm Biocapital Advisors L.P. office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, David Kim serves as the Chief Operating Officer and Chief Compliance Officer at Paradigm Biocapital Advisors L.P..
In the most recent 13F filing, Paradigm Biocapital Advisors L.P. revealed that it had opened a new position in
Merus N.V and bought 2,019,814 shares worth $120 billion.
This means they effectively own approximately 0.1% of the company.
Merus N.V makes up
9.7%
of the fund's Health Care sector allocation and has grown its share price by 120.9% in the past year.
The investment fund also strengthened its position in Nuvalent Inc by buying
393,848 additional shares.
This makes their stake in Nuvalent Inc total 4,571,678 shares worth $347 billion.
On the other hand, there are companies that Paradigm Biocapital Advisors L.P. is getting rid of from its portfolio.
Paradigm Biocapital Advisors L.P. closed its position in Immunocore Hldgs Plc on 14th August 2024.
It sold the previously owned 1,787,176 shares for $116 billion.
David Kim also disclosed a decreased stake in Argenx Se by approximately 0.1%.
This leaves the value of the investment at $231 billion and 538,139 shares.
The two most similar investment funds to Paradigm Biocapital Advisors L.P. are Harvest Portfolios and First Foundation Advisors. They manage $2.61 trillion and $2.61 trillion respectively.
Paradigm Biocapital Advisors L.P.’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 47.4% of
the total portfolio value.
The fund focuses on investments in the United States as
40.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
6% of the total holdings value.
On the other hand, large-cap stocks make up only 2.9% of the portfolio.
The average market cap of the portfolio companies is close to $2.3 billion.
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Nuvalent Inc |
9.43%
4,571,678
|
$346,807,493,000 | 13.27% |
| Argenx Se |
2.53%
538,139
|
$231,421,296,000 | 8.86% |
| Arcellx Inc |
0.79%
3,848,095
|
$212,376,363,000 | 8.13% |
| Revolution Medicines Inc |
80.42%
5,259,089
|
$204,105,244,000 | 7.81% |
| Sarepta Therapeutics Inc |
12.13%
947,574
|
$149,716,692,000 | 5.73% |
| Disc Medicine Inc |
13.17%
2,704,718
|
$121,901,640,000 | 4.67% |
| Merus N.V |
Opened
2,019,814
|
$119,512,394,000 | 4.57% |
| Immunocore Hldgs Plc |
Closed
1,787,176
|
$116,166,440,000 | |
| Crinetics Pharmaceuticals In |
19.57%
2,513,302
|
$112,570,797,000 | 4.31% |
| Cerevel Therapeutics Hldng I |
No change
2,330,508
|
$95,294,472,000 | 3.65% |
| Kura Oncology Inc |
44.78%
4,539,381
|
$93,465,855,000 | 3.58% |
| Ascendis Pharma A/S |
30.78%
664,307
|
$90,598,189,000 | 3.47% |
| Olema Pharmaceuticals, Inc. |
No change
7,903,600
|
$85,516,952,000 | 3.27% |
| Alpine Immune Sciences Inc |
Closed
2,121,163
|
$84,082,901,000 | |
| Bicycle Therapeutics plc |
Closed
3,246,759
|
$80,844,299,000 | |
| Xenon Pharmaceuticals Inc |
17.77%
2,043,280
|
$79,667,487,000 | 3.05% |
| Tarsus Pharmaceuticals, Inc. |
14.95%
2,435,416
|
$66,194,607,000 | 2.53% |
| Janux Therapeutics Inc |
Opened
1,564,452
|
$65,534,894,000 | 2.51% |
| Arvinas Inc |
6.76%
2,438,149
|
$64,903,526,000 | 2.48% |
| Legend Biotech Corp |
39.29%
1,203,308
|
$53,294,511,000 | 2.04% |
| Vaxcyte, Inc. |
49.42%
627,202
|
$47,360,023,000 | 1.81% |
| Y-Mabs Therapeutics Inc |
73.29%
3,870,594
|
$46,756,776,000 | 1.79% |
| Edgewise Therapeutics Inc |
4.94%
2,325,449
|
$41,881,336,000 | 1.60% |
| Autolus Therapeutics plc |
Closed
6,425,803
|
$40,996,623,000 | |
| Immatics N.v |
21.39%
3,421,965
|
$39,763,233,000 | 1.52% |
| Viridian Therapeutics Inc |
42.43%
2,896,349
|
$37,681,500,000 | 1.44% |
| Immunovant Inc |
70.56%
1,362,827
|
$35,978,633,000 | 1.38% |
| Cogent Biosciences, Inc. |
Opened
3,624,342
|
$30,553,203,000 | 1.17% |
| BridgeBio Pharma Inc |
Opened
1,089,492
|
$27,596,832,000 | 1.06% |
| Cullinan Therapeutics Inc |
14.45%
1,542,805
|
$26,906,519,000 | 1.03% |
| Erasca Inc |
Opened
7,250,000
|
$17,110,000,000 | 0.65% |
| Zentalis Pharmaceuticals, Llc |
Closed
944,917
|
$14,891,892,000 | |
| COMPASS Pathways plc |
2.30%
2,335,926
|
$14,108,993,000 | 0.54% |
| Apogee Therapeutics Inc |
No change
330,000
|
$12,985,500,000 | 0.50% |
| Agios Pharmaceuticals Inc |
Closed
400,000
|
$11,696,000,000 | |
| Caribou Biosciences Inc |
Closed
2,172,620
|
$11,167,267,000 | |
| Verona Pharma Plc |
Opened
721,087
|
$10,426,918,000 | 0.40% |
| ALX Oncology Holdings Inc. |
Opened
1,575,605
|
$9,500,898,000 | 0.36% |
| Perspective Therapeutics Inc |
Opened
919,692
|
$9,169,329,000 | 0.35% |
| Vor Biopharma Inc |
No change
6,457,293
|
$6,457,293,000 | 0.25% |
| Acrivon Therapeutics Inc |
Opened
659,724
|
$3,826,399,000 | 0.15% |
| Cargo Therapeutics Inc |
Closed
147,959
|
$3,302,445,000 | |
| Tscan Therapeutics Inc |
Opened
353,886
|
$2,070,233,000 | 0.08% |
| Kyverna Therapeutics Inc |
Closed
50,000
|
$1,242,000,000 | |
| No transactions found | |||
| Showing first 500 out of 44 holdings | |||